Finzati - Logo
ABBV logo

AbbVie Inc.

ABBV • Drug Manufacturers - General
$288.62
▲ +5.94 (+2.10%)
Current price
EarningsLatest report: Jun 30, 2026
BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$510.15B
Growth
8.9%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 6.9%Positive free cash flow · 10.01Consistent free cash flow · 5/5Expensive earnings multiple · 96.26Weak liquidity · 0.67
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$288.62
Change2.10%
Shares Out1.77B
Market Cap$510.15B
Enterprise Value$574.41B
52W Range190.75 - 267.47
Beta0.28
P/E80.72
P/S7.92
P/B17.77
P/FCF26.72
EV/Sales8.92

Investment DNA

How strong this company looks for long-term investors

57
out of 100
Business Quality
Margins, moat, returns
61/100
Financial Strength
Debt, cash, stability
38/100
Growth Potential
Revenue and expansion
30/100
Price Attractiveness
Cheap or expensive today
40/100
Why this score▼
Stable or improving margins · 6.9%Positive free cash flow · 10.01Consistent free cash flow · 5/5Expensive earnings multiple · 96.26Weak liquidity · 0.67Negative growth trend

Analyst view

Analyst sentiment and price target

ABBV
Analyst sentiment
Based on 44 analyst votes · 2026-10-20
85/100
Bullish
Bullish
32
Hold
11
Bearish
1
Price Target
2026-08-05
Low
$235.00
Mean
$283.92
Median
$292.50
High
$300.00

Company Overview

IPO: 1/2/2013
Industry: Drug Manufacturers - General
P/B i: 17.77
Debt / Equity i: -21.12
Operating Margin: 32.85%
Net Margin: 6.91%
ROE i: -
ROIC: -

Financial Health

Score8 / 20
Debt / Equity: -21.12
Current Ratio: 0.67
Quick Ratio: 0.56
Status: Moderate

Warnings

  • Weak Liquidity
  • Weak quick ratio

Insider Transactions

Recent executive and insider activity

Quaggin Susan E
Transaction: 06/30/2026
BUY
Change
+62
Price
$251.64
Filing
07/02/2026
Type
BUY
RAPP EDWARD J
Transaction: 06/30/2026
BUY
Change
+134
Price
$251.64
Filing
07/02/2026
Type
BUY
AUSTIN ROXANNE S
Transaction: 05/08/2026
BUY
Change
+1,118
Price
Not reported
Filing
05/12/2026
Type
BUY